Laekna Announces Clinical Collaboration with Lilly on LAE102, a Novel Obesity Drug Targeting ActRIIA, Driving Share Price Surge of 36.8%
Laekna Therapeutics
Innovative Drug Developer
Eli Lilly
Global Pharmaceutical R&D and Production Company
On November 20, Laekna Therapeutics announced that it had signed a clinical collaboration agreement with Eli Lilly and Company, aiming to support and accelerateLAE102 Global Clinical Development for Obesity Treatment. According to the agreement,Eli Lilly will be responsible for conducting a Phase I study in the United States and bearing the associated costs. Laekna Therapeutics will retain global rights to LAE102.. PossiblyAffected by this news, Laekna Therapeutics' stock price continued to rise today.The intraday maximum increase reached 36.79%.。
Screenshot source:Laekna Therapeutics Announcement
LAE102 is a self-developed product of Laekna Therapeutics.Monoclonal Antibody Targeting Act RIIAAct RIIA is a receptor that plays an important role in muscle regeneration and fat metabolism. In preclinical models, LAE102 has demonstrated the effect of increasing muscle and reducing fat.
According to the announcement from Laekna Therapeutics,LAE102 in combination with GLP-1 receptor agonists can further reduce fat and significantly decrease muscle loss caused by GLP-1 receptor agonists., making LAE102 a high-quality weight control candidate drug.LAE102 has been approved in China for clinical research targeting overweight and/or obesity indications.
Insight database shows that globally there are 8 drugs in development targeting Act RIIA (only active status is counted).But in the obesity indication track, Laekna Therapeutics' LAE102 is the first Act RIIA-targeted drug to enter the clinical stage.。
Currently, Laekna Therapeutics is conducting a randomized, double-blind, placebo-controlled, single and multiple ascending dose study via intravenous infusion (IV) and subcutaneous injection (SC) Two modes of administration to evaluate the safety, tolerability, and pharmacokinetics of LAE102 injection in healthy adult subjects and overweight/obese subjects. In October this year, Laekna Therapeutics announced the single-dose escalation of this Phase I clinical trial (SAD) The subcutaneous injection part of the study has been initiated.
Laekna Therapeutics, founded in 2016, is committed to bringing novel therapies to patients worldwide suffering from cancer, metabolic diseases, and liver fibrosis, and officially listed on the Hong Kong Stock Exchange in July 2023. PerhapsImpacted by the news of cooperation with Eli Lilly, Laekna Therapeutics' stock price has been rising since the market opened today, with the highest intraday increase reaching 36.79%.Since then, although there has been a pullback, the latest increase is still 29%.
Screenshot source: Baidu Stock Express
